The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Pliukhova A.A.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

Budzinskaia M.V.

FGBU "Nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ" RAMN, Moskva

The role of anti-VEGF therapy in geographic atrophy progression

Authors:

Pliukhova A.A., Budzinskaia M.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2018;134(5): 289‑293

Read: 2789 times


To cite this article:

Pliukhova AA, Budzinskaia MV. The role of anti-VEGF therapy in geographic atrophy progression. Russian Annals of Ophthalmology. 2018;134(5):289‑293. (In Russ.)
https://doi.org/10.17116/oftalma2018134051289

Recommended articles:

References:

  1. Danis RP, Lavine JA, Domalpally A. Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects. Clin Ophthalmol. 2015;9:2159–74. https://doi.org/10.2147/OPTH.S92359
  2. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015
  3. Balashevich L. I., Izmailov A. S., Ulitina A. Y.A Modified classification of clinical age-related macular degeneration. Oftal’mologicheskie vedomosti. 2011;4(4):41-47. (In Russ.)
  4. Gass J.D. Drusen and disciform macular detachment and degeneration.Arch Ophthalmol. 1973 Sep;90(3):206-17.
  5. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology. 2001;108(4):697–704.
  6. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell.2007;130(4):691–703.
  7. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol.2007;171(1):53–67.
  8. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D’Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A.2009;106(44):18751–6.
  9. Schutze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(6):1100–14.e1101.https://doi.org/ 10.1016/j.ajo.2015.02.020
  10. Cavallerano AA., Cummings JP., Freeman PB., et al. Care of patient with age-related macular degeneration. American Optometric Association. Revised 2004
  11. Gemenetzi M, Lotery AJ, Patel PJ. Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye (Lond). 2016 Oct 7. [Epub ahead of print] https://doi.org/10.1038/eye.2016.208
  12. Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol.2015;159(5):915–24.e912. https://doi.org/10.1016/j.ajo.2015.01.032.
  13. Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118(3):523–530. https://doi.org/10.1016/j.ophtha.2010.07.011
  14. Grunwald JE, Pistilli M, Ying GS, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4):809–16. https://doi.org/10.1016/j.ophtha.2014.11.007.
  15. Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1):150–61.https://doi.org/ 10.1016/j.ophtha.2013.08.015.
  16. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet.2013;382(9900):1258–67.https://doi.org/ 10.1016/S0140-6736(13)61501-9
  17. Sadda SR, Tuomi LL, Ding B, et al. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2018 Jun;125(6):878-886. https://doi.org/10.1016/j.ophtha.2017.12.026
  18. Rosenfeld PJ. Optical coherence tomography and the development of antiangiogenic therapies in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016; 57: 14–26 https://doi.org/10.1167/iovs.16-19969
  19. Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM. Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. Ophthalmology.2015;122(1):153–161. https://doi.org/10.1016/j.ophtha.2014.07.046
  20. Balaratnasingam C, Dhrami-Gavazi E, Mccann J, Ghadiali Q, Freund KB. Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration. OPTH Clin Ophthalmol. 2015;9:2355–71. https://doi.org/10.2147/OPTH.S80040
  21. Mantel I, Dirani A, Zola M., et al. Macular Atrophy in Anti-Vascular Endothelial Growth Factor-Treated Neovascular Age-related macular Degeneration: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and Plan Regimen. Retina. 2018 Jan 23. https://doi.org/10.1097/IAE.0000000000002054.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.